At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
AlloExbiological
Likely dose
Not stated in record
Key inclusion· 2
- ✓Diagnosis of Parkinson's Disease
- ✓Understanding and willingness to sign informed consent
Key exclusion· 11
- ✕Active infection
- ✕Active cancer
- ✕Chronic multisystem organ failure
- ✕Pregnancy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Exosome Intranasal Instillation for the Treatment of Parkinson's Disease
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 9, 2021·Updated Apr 17, 2025
In Brief
A Phase 1 clinical trial evaluating AlloEx for Parkinson Disease. Currently recruiting, targeting 20 participants across 1 site.
Detailed Summary
This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes for the treatment of Parkinson's Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesAntigua and Barbuda
Collaborators--
Timeline
Phase 1Recruiting
202220232024202520262027
First PostedDec 2021
Enrollment StartAug 2024
TodayJul 2026
Primary CompletionJan 2027
First PostedDec 9, 2021
Enrollment StartAug 17, 2024
Primary CompletionJan 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2.4 yearsPosted 4.6 years agoPrimary completion in 6 months
Interventions
AlloExbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes